Microbial production of phase I and phase II metabolites of propranolol

References

• Barrett AM, Cullum VA. (1968). The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias. Br J Pharmacol 34:43–55.
   PubMed Web of Science ®Google Scholar
• Baughman TM, Talarico CL, Soglia JR. (2009). Evaluation of the metabolism of propranolol by linear ion trap technology in mouse, rat, dog, monkey, and human cryopreserved hepatocytes. Rapid Commun Mass Spectrom 23:2146–2150.
   PubMed Web of Science ®Google Scholar
• Beaudry F, Yves Le Blanc JC, Coutu M, Ramier I, Moreau JP, Brown NK. (1999). Metabolite profiling study of propranolol in rat using LC/MS/MS analysis. Biomed Chromatogr 13:363–369.
   PubMed Web of Science ®Google Scholar
• Bichara N, Ching MS, Blake CL, Ghabrial H, Smallwood RA. (1996). Propranolol hydroxylation and N-desisopropylation by cytochrome P4502D6: studies using the yeast-expressed enzyme and NADPH/O2 and cumene hydroperoxide-supported reactions. Drug Metab Dispos 24:112–118.
   PubMed Web of Science ®Google Scholar
• Borges KB, Pupo MT, Bonato PS. (2009). Enantioselective analysis of propranolol and 4-hydroxypropranolol by CE with application to biotransformation studies employing endophytic fungi. Electrophoresis 30:3910–3917.
   PubMed Web of Science ®Google Scholar
• Di Nardo G, Fantuzzi A, Sideri A, Panicco P, Sassone C, Giunta C, Gilardi G. (2007). Wild-type CYP102A1 as a biocatalyst: turnover of drugs usually metabolised by human liver enzymes. J Biol Inorg Chem 12:313–323.
   Google Scholar
• Foster BC, Buttar HS, Qureshi SA, McGilveray IJ. (1989). Propranolol metabolism by Cunninghamella bainieri. Xenobiotica 19:539–546.
   PubMed Web of Science ®Google Scholar
• Foster BC, Litster DL, Wilson DL, Ormsby E, Dawson BA. (1992). In vitro assessment of cytotoxicity and biotransformation of propranolol in Cunninghamella echinulata. Xenobiotica 22:1221–1228.
   PubMed Web of Science ®Google Scholar
• Hanioka N, Hayashi K, Shimizudani T, Nagaoka K, Koeda A, Naito S, Narimatsu S. (2008). Stereoselective glucuronidation of propranolol in human and cynomolgus monkey liver microsomes: role of human hepatic UDP-glucuronosyltransferase isoforms, UGT1A9, UGT2B4 and UGT2B7. Pharmacology 82:293–303.
   PubMed Web of Science ®Google Scholar
• Huang H, Chen X, Cui H, Zhong D. (2001). Synthesis of 5-hydroxypropranolol by microbial transformation. Yaowu Shengwu Jishu 8:268–271.
   Google Scholar
• Kinne M, Poraj-Kobielska M, Aranda E, Ullrich R, Hammel KE, Scheibner K, Hofrichter M. (2009). Regioselective preparation of 5-hydroxypropranolol and 4′-hydroxydiclofenac with a fungal peroxygenase. Bioorg Med Chem Lett 19:3085–3087.
   Google Scholar
• Lampinen Salomonsson M, Bondesson U, Hedeland M. (2009). In vitro formation of phase I and II metabolites of propranolol and determination of their structures using chemical derivatization and liquid chromatography–tandem mass spectrometry. J Mass Spectrom 44:742–754.
   Google Scholar
• Luan LJ, Shao Q, Zeng S. (2005). Stereoselectivity and interaction between the glucuronidation of S-(−)- and R-(+)-propranolol in rat hepatic microsomes pretreated with different inducers. Pharmazie 60:221–224.
   Google Scholar
• Masubuchi Y, Hosokawa S, Horie T, Suzuki T, Ohmori S, Kitada M, Narimatsu S. (1994). Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab Dispos 22:909–915.
   PubMed Web of Science ®Google Scholar
• Narimatsu S, Arai T, Masubuchi Y, Horie T, Hosokawa M, Ueno K, Kataoka H, Yamamoto S, Ishikawa T, Cho AK. (2001). Inactivation of rat cytochrome P450 2D enzyme by a further metabolite of 4-hydroxypropranolol, the major and active metabolite of propranolol. Biol Pharm Bull 24:988–994.
   PubMed Web of Science ®Google Scholar
• Nelson WL, Bartels MJ. (1984). Stereoselectivity in the aromatic hydroxylation of propranolol in the rat: use of deuterium labeling and pseudoracemic mixtures. Drug Metab Dispos 12:382–384.
   Google Scholar
• Oatis JE Jr, Baker JP, McCarthy JR, Knapp DR. (1983). Synthesis and chromatographic separation of the glucuronides of (R)- and (S)-propranolol. J Med Chem 26:1687–1691.
   PubMed Web of Science ®Google Scholar
• Oatis JE Jr, Russell MP, Knapp DR, Walle T. (1981). Ring-hydroxylated propranolol: synthesis and beta-receptor antagonist and vasodilating activities of the seven isomers. J Med Chem 24:309–314.
   PubMed Web of Science ®Google Scholar
• Otey CR, Bandara G, Lalonde J, Takahashi K, Arnold FH. (2006). Preparation of human metabolites of propranolol using laboratory-evolved bacterial cytochromes P450. Biotechnol Bioeng 93:494–499.
   PubMed Web of Science ®Google Scholar
• Otton SV, Gillam EM, Lennard MS, Tucker GT, Woods HF. (1990). Propranolol oxidation by human liver microsomes—the use of cumene hydroperoxide to probe isoenzyme specificity and regio- and stereoselectivity. Br J Clin Pharmacol 30:751–760.
   PubMed Web of Science ®Google Scholar
• Pham-Huy C, Sahui-Gnassi A, Saada V, Gramond JP, Galons H, Ellouk-Achard S, Levresse V, Fompeydie D, Claude JR. (1994). Microassay of propranolol enantiomers and conjugates in human plasma and urine by high-performance liquid chromatography after chiral derivatization for pharmacokinetic study. J Pharm Biomed Anal 12:1189–1198.
   Google Scholar
• Silber B, Holford NH, Riegelman S. (1982). Stereoselective disposition and glucuronidation of propranolol in humans. J Pharm Sci 71:699–704.
   PubMed Web of Science ®Google Scholar
• Sten T, Qvisen S, Uutela P, Luukkanen L, Kostiainen R, Finel M. (2006). Prominent but reverse stereoselectivity in propranolol glucuronidation by human UDP-glucuronosyltransferases 1A9 and 1A10. Drug Metab Dispos 34:1488–1494.
   PubMed Web of Science ®Google Scholar
• Thompson JA, Hull JE, Norris KJ. (1981). Glucuronidation of propranolol and 4′-hydroxypropranolol. Substrate specificity and stereoselectivity of rat liver microsomal glucuronyltransferases. Drug Metab Dispos 9:466–471.
   PubMed Web of Science ®Google Scholar
• Tindell GL, Walle T, Gaffney TE. (1972). Rat liver microsomal metabolism of propranolol: identification of seven metabolites by gas chromatography–mass spectrometry. Life Sci II 11:1029–1036.
   Google Scholar
• von Bahr C, Hermansson J, Lind M. (1982). Oxidation of (R)- and (S)-propranolol in human and dog liver microsomes. Species differences in stereoselectivity. J Pharmacol Exp Ther 222:458–462.
   Google Scholar
• Walle T, Oatis JE Jr, Walle UK, Knapp DR. (1982). New ring-hydroxylated metabolites of propranolol: species differences and stereospecific 7-hydroxylation. Drug Metab Dispos 10:122–127.
   Google Scholar
• Walle T, Walle UK, Olanoff LS. (1985). Quantitative account of propranolol metabolism in urine of normal man. Drug Metab Dispos 13:204–209.
   PubMed Web of Science ®Google Scholar
• Yoshimoto K, Echizen H, Chiba K, Tani M, Ishizaki T. (1995). Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers—N-desisopropylation is mediated mainly by CYP1A2. Br J Clin Pharmacol 39:421–431.
   PubMed Web of Science ®Google Scholar
• Yu L, Qian M, Liu Y, Yao T, Zeng S. (2010). Stereoselective metabolism of propranolol glucuronidation by human UDP-glucuronosyltransferases 2B7 and 1A9. Chirality 22:456–461.
   PubMed Web of Science ®Google Scholar
• Yun CH, Kim KH, Kim DH, Jung HC, Pan JG. (2007). The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. Trends Biotechnol 25:289–298.
   Google Scholar